High-Risk Compounding Pharmacies Targeted for FDA Review
This article is for subscribers only.
About 30 “high risk” compounding pharmacies are being targeted by U.S. regulators for inspections over the next two months as part of intensified enforcement efforts after last year’s deadly meningitis outbreak.
The companies primarily make sterile drugs and distribute products to health-care providers nationwide, Erica Jefferson, a spokeswoman for the Food and Drug Administration, said today in a phone interview. The visits, which began Feb. 19 and will continue about two months, are the first proactive inspections the agency has conducted of compounding pharmacies, she said.